Comparing methods to capture circulating tumor cells in metastatic breast or prostate cancer
Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
This one-day test will compare three blood-based methods (CellSearch®, Parsortix®, and SmartCatch®) to see which best finds circulating tumor cells in people with metastatic breast or prostate cancer before they start a new line of treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Claudius Regaud Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06904625 on ClinicalTrials.gov |
What this trial studies
This is a pilot, prospective, single-center study enrolling 36 patients (18 with metastatic breast cancer and 18 with metastatic prostate cancer). Each participant gives blood on one day before initiating a new anti-tumor treatment, and that sample is processed by three different CTC detection techniques: CellSearch®, Parsortix®, and SmartCatch®. The primary aim is to compare the sensitivity of these capture methods for detecting circulating tumor cells. Results will provide comparative data on detection rates across the three platforms in a real-world metastatic setting.
Who should consider this trial
Good fit: Adults (≥18) in France with multi‑metastatic breast or prostate cancer who have not yet started a new line of cancer treatment, have WHO performance status ≤2, and can give informed consent are ideal candidates.
Not a fit: Patients already on a new cancer treatment, with only localized disease, with another active solid tumor (except certain in situ cancers), unable to consent, or unable to comply with procedures are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the trial could identify the most sensitive blood test for detecting circulating tumor cells, which may improve disease monitoring and help guide treatment decisions.
How similar studies have performed: Related technologies such as CellSearch® and Parsortix® have previously detected circulating tumor cells and shown prognostic value, but direct head-to-head comparisons that include SmartCatch® are limited, so this pilot adds novel comparative data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient with breast cancer (whatever the immunohistochemical subtype: triple-negative, RH+/HER2-negative or HER2-positive) or prostate cancer, multi-metastatic, eligible for a new line of treatment. 2. Patient not yet initiated on a new specific treatment for breast or prostate cancer at inclusion. 3. Age ≥ 18 years and WHO ≤ 2 4. Patient affiliated to Social Security scheme in France. 5. Patient having signed informed consent prior to inclusion in the study and prior to any study-specific procedures. Exclusion Criteria: 1. Associated pathology(ies) likely to prevent the study procedure from running smoothly 2. Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures stipulated in the study protocol. 3. Patient deprived of liberty or under legal protection (guardianship, legal protection) 4. Patient who has had another solid tumor (excluding carcinoma in situ of the breast or cervix) within 5 years.
Where this trial is running
Toulouse
- Iuct-O — Toulouse, France (Recruiting)
Study contacts
- Study coordinator: Florence DALENC
- Email: Dalenc.florence@iuct-oncopole.fr
- Phone: 05 31 15 51 22
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.